MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Interstitial lung disease (ILD） is the late pulmonary complications after allogeneic
hematopoietic stem cell transplantation (allo-HSCT) leading to high morbidity and mortality.
At present, the treatment for ILD after allo-HSCT remains in discussion. In this study, the
efficacy of mesenchymal stem cells (MSCs) combined azithromycin as well as glucocorticoid as
the treatment of ILD will be evaluated in the recipients of allo-HSCT.